Anotace:
This study aimed to assess the impact of administering Cheral® (Curcuma longa and Phyllanthus niruri) on the expression of T lymphocytes and regulatory T cells. The research was conducted in vivo using 24 healthy female Wistar rats, which were categorized into four treatment groups: normal (control), dose 1 (156.25 mg/Kg BW), dose 2 (312.5 mg/Kg BW), and dose 3 (468.75 mg/Kg BW). The rats were orally administered Cheral® for a period of 90 days. T lymphocytes and regulatory T cell profiles were analyzed using flow cytometry. The data obtained were subsequently subjected to analysis using SPSS software with One-way ANOVA and Post hoc tests (p-value <0.05). The profiles of T lymphocytes and regulatory T cells following Cheral® administration exhibited diverse outcomes when compared to the normal group. Specifically, dose 2 led to a significant increase in CD4, while dose 1 resulted in a significant increase in CD8. However, the profile of regulatory T cells after Cheral® administration did not exhibit any significant differences when compared to the control group. In conclusion, this research indicates that the compounds present in Cheral® have the potential to modulate the immune system through their effects on T lymphocytes and regulatory T cells.